GLP-1 Tirzepatide Drops — Separating the Claims from the Facts

The biggest misconception: tirzepatide comes in a liquid you can take by mouth

A question our prescribers hear most weeks, usually from people who've seen social-media listings, is whether tirzepatide is available as drops you swallow or apply under the tongue. The short answer is no, and understanding why helps explain what makes this medicine work at all.

Tirzepatide is a large peptide molecule. Peptides break down rapidly in the digestive tract; taken orally without very specific pharmaceutical engineering, the active ingredient would be destroyed before it reached the bloodstream. The Mounjaro pen bypasses this entirely by delivering the medicine directly under the skin, where it absorbs slowly and steadily over the course of a week. That slow-release profile is part of why it produces the consistent appetite effects reported in clinical trials.

Products sold online as tirzepatide drops sidestep this biology, claiming sublingual absorption or some other route, but none of these products hold MHRA authorisation, and no published trial data supports their efficacy or safety. The NHS tirzepatide medicines page covers the approved medicine clearly: it is an injection, full stop. If you're looking at a liquid version and wondering whether it's worth trying, the honest clinical answer is that there's no evidence it is the same thing.

What unlicensed drop products actually are, and why that matters

The MHRA has consistently warned that medicines sold online without a valid UK authorisation pose real risk. Fake or unregulated formulations may contain no active ingredient at all, the wrong ingredient, or inconsistent concentrations. For a medicine where dose titration is closely managed by a prescriber (starting at 2.5 mg and adjusting over months) an unverified liquid with no quality control is particularly hazardous.

This isn't abstract concern. The MHRA's enforcement work through 2024 and 2025 uncovered around 20 million doses of illegally traded weight-loss medicines (approximately £45 million street value), including the first illicit UK site producing counterfeit tirzepatide pens. Drops and liquids from unverified sellers sit in the same regulatory no-man's-land. You can read about the specific claims made about Mounjaro drops and why none of them hold up under scrutiny.

For anyone who found drop products appealing because needles feel daunting, that's completely understandable. It's worth knowing that the Mounjaro pen uses a very fine, short needle and is designed to be self-administered at home with minimal discomfort. The needle concern is real, but it rarely feels as significant in practice as it does in anticipation.

How the licensed injection works, and what the evidence shows

Tirzepatide activates two hormone receptors simultaneously: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Both are involved in regulating appetite, fullness and blood-sugar balance. By targeting both pathways, it produces effects on appetite and satiety that are more pronounced than single-pathway agents, which is reflected in the trial data.

In the SURMOUNT-1 trial (involving 2,539 adults with obesity) participants using tirzepatide 15 mg lost around 20–21% of body weight on average over 72 weeks, alongside a reduced-calorie diet and increased activity. NICE reviewed this evidence thoroughly in its appraisal of tirzepatide, published as TA1026, before recommending it for use in the UK. These results come from the injection. There are no equivalent data for any drop formulation, because no drop formulation has been through a regulated clinical programme.

If you want to understand how this evidence translates to real-world use, the page on whether tirzepatide drops work goes deeper on this comparison, though the title is somewhat rhetorical, because the licensed form is the one with the evidence base.

The legitimate route to tirzepatide in the UK

Tirzepatide is a prescription-only medicine. Getting it legally means a clinical consultation with a registered prescriber who can assess your health history, current medicines, BMI and any relevant conditions. General eligibility under the UK licence covers adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. But BMI alone is never the whole picture, a prescriber looks at the full clinical profile.

At nume, every consultation is reviewed the same day by a GPhC-registered Independent Prescriber. There are no algorithms making that call. You can read more about our approach on the about us page, or explore the broader weight-loss treatment options we offer. For anyone comparing drop products to the genuine article, it's also worth reading independent accounts on the tirzepatide GLP-1 drops reviews page, which addresses what people report from unregulated versions.

The interest in alternative formats is understandable, and it reflects how much demand there is for accessible, effective weight-loss medicine. The answer, though, isn't a workaround, it's the licensed medicine through a verified, regulated pharmacy. You can verify any UK online pharmacy on the GPhC register before handing over any personal or payment information. That check takes about thirty seconds and is worth every one of them.

If you'd like to find out whether tirzepatide oral drops are something you've been considering, or whether the licensed injection is clinically appropriate for you, check your eligibility with a free consultation, a prescriber will review your answers the same day.